文献速递前列腺癌

阿帕他胺治疗前列腺癌的总生存期最终分析

Apalutamide and Overall Survival in Prostate Cancer.
PubMed 文献 · Eur Urol · 2020-09-06

SPARTAN研究最终分析显示,在非转移性去势抵抗性前列腺癌(nmCRPC)患者中,阿帕他胺联合雄激素剥夺治疗较安慰剂显著延长中位总生存期(73.9 vs 59.9个月,HR 0.78,P=0.016),并延长至细胞毒性化疗时间(HR 0.63,P=0.0002)。

要点

  • 阿帕他胺组至细胞毒性化疗时间显著延长(HR 0.63)。
  • 尽管安慰剂组有19%交叉换药,OS获益仍显著。

核心结论

  • 阿帕他胺较安慰剂显著延长nmCRPC患者的总生存期,死亡风险降低22%。

研究设计与样本

  • SPARTAN为3期随机双盲研究,纳入1207例nmCRPC患者,按2:1随机接受阿帕他胺240mg/d或安慰剂,均联合持续雄激素剥夺治疗。

主要发现

  • 中位随访52个月,共发生428例死亡,阿帕他胺组中位OS为73.9个月,安慰剂组为59.9个月(HR 0.78,95%CI 0.64-0.96,P=0.016)。
  • 阿帕他胺组至细胞毒性化疗时间较安慰剂组延长(HR 0.63,95%CI 0.49-0.81,P=0.0002)。
  • 阿帕他胺组和安慰剂组因疾病进展停药率分别为43%和74%,因不良事件停药率分别为15%和8.4%。
  • 安慰剂组76例(19%)患者交叉接受阿帕他胺,阿帕他胺组371例(46%)、安慰剂组338例(84%)接受了后续延长生存治疗。

关键数值与推荐

  • 中位OS:阿帕他胺组73.9个月 vs 安慰剂组59.9个月(HR 0.78,95%CI 0.64-0.96,P=0.016)。
  • 至细胞毒性化疗时间:HR 0.63(95%CI 0.49-0.81,P=0.0002)。
  • 因不良事件停药率:阿帕他胺组15% vs 安慰剂组8.4%。

临床怎么用

  • 对于nmCRPC且PSA倍增时间≤10个月的患者,阿帕他胺联合ADT可显著延长总生存期并推迟化疗需求。

局限性

  • 安慰剂组有19%患者交叉接受阿帕他胺,可能低估OS获益。
  • 安全性分析中,不良事件经暴露时间调整后皮疹发生率差异最大。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The phase 3 SPARTAN study evaluated apalutamide versus placebo in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) and prostate-specific antigen doubling time of ≤10 mo. At primary analysis, apalutamide improved median metastasis-free survival (MFS) by 2 yr and overall survival (OS) data were immature. OBJECTIVE: We report the prespecified event-driven final analysis for OS. DESIGN, SETTING, AND PARTICIPANTS: A total of 1207 patients with nmCRPC (diagnosed by conventional imaging) were randomised 2:1 to apalutamide (240mg/d) or placebo, plus on-going androgen deprivation therapy. After MFS was met and the study was unblinded, 76 (19%) patients still receiving placebo crossed over to apalutamide. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: OS and time to cytotoxic chemotherapy (TTChemo) were analysed by group-sequential testing with O'Brien-Fleming-type alpha spending function. RESULTS AND LIMITATIONS: At median 52-mo follow-up, 428 deaths had occurred. The median treatment duration was 32.9 mo for apalutamide group and 11.5 mo for placebo group. Median OS was markedly longer with apalutamide versus placebo, reaching prespecified statistical significance (73.9 vs 59.9 mo, hazard ratio [HR]: 0.78 [95% confidence interval {CI}, 0.64-0.96]; p=0.016). Apalutamide also lengthened TTChemo versus placebo (HR: 0.63 [95% CI, 0.49-0.81]; p=0.0002). Discontinuation rates in apalutamide and placebo groups due to progressive disease were 43% and 74%, and due to adverse events 15% and 8.4%, respectively. Subsequent life-prolonging therapy was received by 371 (46%) patients in the apalutamide arm and by 338 (84%) patients in the placebo arm including 59 patients who received apalutamide after crossover. Safety was consistent with previous reports; when adverse events were adjusted for treatment exposure, rash had the greatest difference of incidence between the apalutamide and placebo groups. CONCLUSIONS: Extension of OS with apalutamide compared with placebo conferred impactful benefit in patients with nmCRPC. There was a 22% reduction in the hazard of death in the apalutamide group despite 19% crossover (placebo to apalutamide) and higher rates of subsequent therapy in the placebo group. PATIENT SUMMARY: With data presented herein, all primary and secondary study end points of SPARTAN were met; findings demonstrate the value of apalutamide as a treatment option for nonmetastatic castration-resistant prostate cancer.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Smith MR, Saad F, Chowdhury S, et al. Apalutamide and Overall Survival in Prostate Cancer. Eur Urol. 2020. PMID: 32907777. doi:10.1016/j.eururo.2020.08.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。